Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

2013 Journal of Hepatology 59;4 (675-683)

BACKGROUND & AIMS: Chronic hepatitis C is both a virologic and fibrotic disease and complications can occur in patients with sustained virologic response (SVR) with residual fibrosis. Due to the limitations of repeated biopsies, no studies have assessed the dynamic of fibrosis before and after treatment. Using biopsy as reference, FibroTest has been validated as a biomarker of fibrosis progression and regression, with similar prognostic values. The aim was to estimate the impact of SVR on the dynamic of fibrosis presumed by FibroTest. METHODS: In a prospective cohort, the main end point was the 10-year regression rate of fibrosis, defined as a minimum 0.20 decrease in FibroTest, equivalent to one METAVIR stage. RESULTS: A total of 933 patients with both repeated FibroTest and transient elastography were included. At 10 years, among the 415 patients with baseline advanced fibrosis, 49% (95% CI 33-64%) of the 108 SVR had a regression, which was greater than in the 219 non-responders [23% (14-33%; p

Pubmed : 23712051